Latest News & Features

Reset all filters
Article Type
Channels & Sectors

Refine Search
Big Pharma
The UK Supreme Court ruling involving Pfizer and Flynn is important for any company considering an appeal against the regulator, say Sophie Lawrance and James Batsford of Bristows.   30 June 2022
The COVID-19 IP agreement promises to enable developing countries more autonomy to produce and distribute vaccines, but it has attracted many critics, finds Sarah Speight.   23 June 2022
Big Pharma
The England and Wales Patent Court affirmed its power to grant injunctions for pre-grant patents—but not for Novartis, explains Azadeh Vahdat of EIP.   21 June 2022
Why does Japan have no reverse payments culture? Takanori Abe of Abe & Partners unpicks a complex issue.   27 May 2022
UK legislation to streamline gene-editing technology research is promising for innovation, but presents potential complications for IP, finds Sarah Speight.   26 May 2022
The case reinforced the need for interim injunction applications to be made as quickly as possible, explains Lydia Birch of EIP.   26 May 2022
South Africa’s Supreme Court has declared regulations on complementary medicines invalid, explain Kareema Shaik and Jenny Pienaar of Adams & Adams.   23 May 2022
A pressing need for more non-invasive prenatal tests is leading to increasing IP activity and commercial interest, say Fran Salisbury and Alice Jefferies of Mewburn Ellis.   19 April 2022
Big Pharma
The ‘joint applicants’ approach to PCT applications would provide an elegant solution to issues of who is entitled to priority claims in PCT applications, suggests Chiara Banas of EIP.   14 April 2022
A new referral to the European Patent Office’s enlarged board of appeal will determine whether post-filed data can be used to support inventive steps in patentability, as Sarah Gibbs of Appleyard Lees reports.   7 April 2022